ArticleMedicine2026
Comparison analysis of the triglyceride-glucose index, triglyceride-glucose and frailty index in cardiovascular disease and mortality association among patients with rheumatoid arthritis: A population-based cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cardiovascular disease (CVD) is a major cause of excess mortality among patients with rheumatoid arthritis (RA). Conventional risk assessment may not fully capture the metabolic abnormalities and physiological vulnerability associated with RA. We investigated whether the triglyceride-glucose-frailty index (TyG-FI), which combines a surrogate marker of insulin resistance with accumulated health deficits, was associated with prevalent CVD and cardiovascular mortality among adults with RA. We analyzed 1090 adults with self-reported RA from 10 cycles of the National Health and Nutrition Examination Survey conducted between 1999 and 2018. TyG-FI was calculated as the product of the triglyceride-glucose index and a 49-item deficit-accumulation frailty index. Multivariable logistic regression was used to examine the association with prevalent CVD, whereas Cox proportional hazards regression was used to examine cardiovascular mortality. Restricted cubic splines, subgroup analyses, sensitivity analyses, and discrimination analyses were conducted as secondary analyses. In the fully adjusted models, each 1-unit higher TyG-FI was associated with higher odds of prevalent CVD (odds ratio, 4.50; 95% confidence interval, 3.20-6.33) and a higher hazard of cardiovascular mortality (hazard ratio, 1.77; 95% confidence interval, 1.16-2.70). The reported areas under the receiver operating characteristic curve were 0.80 for prevalent CVD and 0.81 for cardiovascular mortality in models incorporating TyG-FI, compared with 0.73 and 0.80, respectively, in models incorporating TyG. An exploratory subgroup analysis suggested a stronger association between TyG-FI and prevalent CVD among participants aged ≤65 years (P for interaction = .044). Higher TyG-FI was associated with prevalent CVD and cardiovascular mortality among US adults with self-reported RA. TyG-FI may capture complementary metabolic and frailty-related information; however, its incremental predictive value, calibration, clinical utility, and external validity require further evaluation before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.